Develops novel small molecule drugs for neuropsychiatric and neurologic diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 134% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 20.6× for every dollar of annual revenue.
Analysts' average target sits 25% below today's price.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 134% a year on average.
The company sells $680.9M a year; the problem isn’t sales — it’s costs running above that number.
There is $1.0B in the vault; even if every debt were paid off, $984.1M would remain.
A loss of $74.7M against $680.9M in annual sales.
The stock trades 25% above the average analyst price target.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.